01—Abstract
Summary
Summary of the 10-K filed February 11, 2016. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $88.9 milliona, or $1.05 per share, for 2015, compared with a net loss of $60.5 million in 2014.
Revenue was $19.8 millionb, all recognized from the up-front license fee under the March 2015 Mitsubishi Tanabe collaboration for valbenazine in Japan and other select Asian markets. Operating expenses rose to $114.0 million from $64.4 million, driven by research and development expense of $81.5 million (up from $46.4 million) and general and administrative expense of $32.5 million (up from $18.0 million). The company had no approved products and an accumulated deficit of $915.2 million at December 31, 2015.
The company's two lead late-stage programs are elagolix, a GnRH antagonist partnered with AbbVie for endometriosis and uterine fibroids, and valbenazine (NBI-98854), a VMAT2 inhibitor in Phase III for tardive dyskinesia and Phase II for Tourette syndrome. The filing states that AbbVie is targeting a 2017 New Drug Application filing for elagolix in endometriosis, and that the company expects to file a New Drug Application for valbenazine in tardive dyskinesia in 2016. The company also expects to increase general and administrative expense significantly in 2016 to prepare for valbenazine's commercialization, and expects a net loss in 2016.
At December 31, 2015, cash, cash equivalents and investments totaled $461.7 millionc, up from $231.3 million a year earlier, following a $270.7 million net equity offering in February 2015. Management states that existing capital resources, investment income and future strategic alliance payments will be sufficient for at least the next 12 months. Mount Sinai filed a complaint in December 2015 alleging that the company breached its GnRH license by entering the AbbVie collaboration; the company intends to defend the claims vigorously.
02—Key points
Key Highlights
- Net loss widened to $88.9 million ($1.05 per share) in 2015 from $60.5 million ($0.81 per share) in 2014.
- Revenue of $19.8 million in 2015 came entirely from the $30 million up-front license fee under the Mitsubishi Tanabe valbenazine agreement; no product revenue to date.
- R&D expense rose to $81.5 million from $46.4 million, mainly reflecting the VMAT2 Phase III program; G&A expense rose to $32.5 million from $18.0 million.
- Cash, cash equivalents and investments were $461.7 million at year-end 2015, versus $231.3 million a year earlier, after a February 2015 public offering netting $270.7 million.
- Valbenazine's Kinect 3 Phase III study met its primary endpoint at the 80mg dose (AIMS reduction of 3.1 points versus placebo, p<0.0001), and the company expects to file an NDA in tardive dyskinesia in 2016.
- Elagolix Phase III endometriosis trials (Violet and Solstice) met co-primary endpoints; AbbVie is targeting a 2017 NDA filing.
- Mount Sinai filed suit in December 2015 alleging breach of the GnRH license, seeking unspecified damages and future sublicensing fees; the company believes it has meritorious defenses.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2015filed February 11, 2016Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $19.77M$0 | — |
| Cost of Revenue | $0— | — |
| Gross Profit | $19.77M— | — |
| R&D Expenses | $81.49M$46.42M | +75.5% |
| SG&A Expenses | $32.48M— | — |
| Operating Expenses | $113.97M$64.41M | +76.9% |
| Operating Income | -$94.20M-$64.41M | −46.3% |
| Interest Expense | $0— | — |
| Net Income | -$88.93M-$60.54M | −46.9% |
| EPS (Basic) | $-1.05$-0.81 | −29.6% |
| EPS (Diluted) | $-1.05$-0.81 | −29.6% |
| Shares Outstanding (Basic) | 84.50M74.58M | +13.3% |
| Shares Outstanding (Diluted) | 84.50M74.58M | +13.3% |
05—Questions
Frequently Asked Questions
How much cash does Neurocrine have, and how long will it last?
Cash, cash equivalents and investments totaled $461.7 million at December 31, 2015. The company believes existing capital resources, investment income and future payments under its strategic alliances will be sufficient for at least the next 12 months, but it notes that additional funding may be needed for its programs and that any equity financing would be dilutive.
Does Neurocrine expect to be profitable soon?
No. The filing states the company does not expect to be profitable or generate positive cash flow from operations for 2016, and it expects a net loss in 2016, mainly due to significantly higher general and administrative expense as it prepares to commercialize valbenazine in tardive dyskinesia.
When could Neurocrine's lead products reach the market?
The company states it expects to file a New Drug Application for valbenazine in tardive dyskinesia in 2016. AbbVie is targeting a 2017 New Drug Application filing for elagolix in endometriosis. The filing describes these as expected timelines, and no product has yet received regulatory approval.
What is the main legal risk disclosed in the filing?
Mount Sinai filed a complaint on December 1, 2015 alleging that Neurocrine breached its 1999 GnRH license agreement by entering the exclusive AbbVie collaboration. Mount Sinai seeks unspecified monetary damages, future sublicensing fees and attorney's fees. Neurocrine believes it has meritorious defenses but cannot predict the outcome.
06—Continue